Celgene Corp (CELG) is fresh off the heels of a new multi-year high, rebounding sharply after shares fell with the market in early August. With estimates on the rise and a bullish growth projection, this Zacks #1 Rank stock is showing some nice upward momentum.
Company Description
Celgene Corp is a biopharmaceutical company that specializes in cancer and antiinflamatory diseases. The company was founded in 1980 and has a market cap of $29 billion.
Celgene is one of the few stocks that has retraced back to its 52-week high after the recent sell off. The bullish movement comes on the heels of strong Q2 results from late July that came in ahead of expectations.
Second-Quarter Results
Revenue for the period was up 38% from last year to $1.18 billion. Earnings also looked good, coming in at 78 cents, one penny ahead of the Zacks Consensus Estimate.
The good quarter was led by the company’s top seller, REVLIMID, a cancer drug that saw sales increase 35% from last year to $795 million.
Celgene’s breast cancer drug ABRAXANE saw sales jump to $95 million. Vidaza, another bone marrow cancer drug saw sales increase 23% to $162 million.
Estimates
We saw some pretty solid movement in estimates off the good quarter, with the current year adding 15 cents to $3.25. The next-year estimate is pegged at $3.83, a bullish 18% growth projection.
Valuation
With a PEG ratio of 1.11, CELG trades at a slight premium to the benchmark of 1 for value.
12-Month Chart
On the chart, CELG has rebounded nicely after taking a dip with the market in early August. As it stands, shares are trading at a multi-year high.
Michael Vodicka is the Momentum Stock Strategist for Zacks.com. He is also the Editor in charge of the market-beating Zacks Whisper Trader Service.
CELGENE CORP (CELG): Free Stock Analysis Report
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment